Bristol-Myers Squibb Company (BMY) | |||
---|---|---|---|
67.68 0.7 (1.05%) | 03-24 16:00 | ||
Open: | 67.2 | Pre. Close: | 66.98 |
High: | 67.775 | Low: | 66.69 |
Volume: | 6,058,833 | Market Cap: | 142,045(M) |
Stock Technical Analysis | |
---|---|
Overall: | ![]() ![]() ![]() |
Target: | Six months: 81.08 One year: 84.07 |
Support: | Support1: 65.28 Support2: 54.31 |
Resistance: | Resistance1: 69.42 Resistance2: 71.98 |
Pivot: | 67.11 ![]() |
Moving Averages: | MA(5): 67.33 ![]() MA(20): 67.67 ![]() MA(100): 73.51 ![]() MA(250): 73.78 ![]() |
MACD: | MACD(12,26): -1.02 ![]() Signal(12,26,9): -1.23 ![]() |
%K %D: | %K(14,3): 45.92 ![]() %D(3): 45.09 ![]() |
RSI: | RSI(14): 44.27 ![]() |
52-Week: | High: 81.44 Low: 65.28 Change(%): -8.2 |
Average Vol(K): | 3-Month: 8118 10-Days: 9262 |
Prices Prediction (Update @5:00pm) | ||
---|---|---|
If tomorrow: | Open lower | Open higher |
High: | 67.814 - 68.148 | 68.148 - 68.487 |
Low: | 65.898 - 66.247 | 66.247 - 66.601 |
Close: | 67.118 - 67.672 | 67.672 - 68.233 |
Price, MAs and Bollinger Bands |
---|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BMY ] has closed below upper band by 31.6%. Bollinger Bands are 47.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend. |
Company profile |
---|
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York. |
Stock chart |
---|
![]() |
Financial Analysis | |
---|---|
Price to Book Value: | Outperform |
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. | |
Price to Earnings: | Outperform |
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). | |
Discounted cash flow: | Outperform |
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. | |
Return on Assets: | Neutral |
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. | |
Return on Equity: | Neutral |
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. | |
Debt to Equity: | Outperform |
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Stock Basics & Statistics | |
---|---|
Exchange: New York Stock Exchange | |
Sector: Healthcare | |
Industry: Drug Manufacturers—General | |
Shares Out. (M) | 2100.00 |
Shares Float (M) | 2100.00 |
% Held by Insiders | 0.07 |
% Held by Institutions | 78.84 |
Shares Short (K) | 17020 |
Shares Short Prior Month (K) | 20720 |
Stock Financials | |
---|---|
EPS | 2.910 |
Book Value (p.s.) | 14.810 |
Profit Margin | 13.71 |
Operating Margin | 21.40 |
Return on Assets (ttm) | 6.0 |
Return on Equity (ttm) | 18.9 |
Qtrly Rev. Growth | -4.8 |
Gross Profit (p.s.) | 17.324 |
Sales Per Share | 21.981 |
EBITDA (p.s.) | 9.600 |
Qtrly Earnings Growth | -11.40 |
Operating Cash Flow (M) | 13070.00 |
Levered Free Cash Flow (M) | 13830.00 |
Stock Valuation | |
---|---|
PE Ratio | 23.26 |
PEG Ratio | 2.05 |
Price to Book value | 4.57 |
Price to Sales | 3.08 |
Price to Cash Flow | 10.87 |
Stock Dividends | |
---|---|
Dividend | 0.570 |
Dividend Yield | 0.01 |
Dividend Growth |